Skip to main content
. 2020 Jun 3;22(6):e17184. doi: 10.2196/17184

Table 2.

Phase 2 participant characteristics.

Variable Interview participants (n=12) Survey respondents (not interviewed; n=17)
Child’s current age (years), mean (SD) 12.3 (3.1) 12.6 (3.7)
Child’s age at diagnosis with T1Da (years), mean (SD) 7.9 (2.8) 7.3 (3.4)
Child’s age at diagnosis with ASDb (years), mean (SD) 5.6 (3.5) 5.6 (3.8)
Self-reported HbA1cc, % (mmol/mol) 8.6 (70) 7.7 (61)
Laboratory confirmed HbA1c, % (mmol/mol) 8.7 (72) N/Ad
Country of residence, n (%)

United States 12 (100) 17 (100)
Gender, n (%)

Male 7 (58) 10 (59)

Female 5 (42) 7 (41)
Race, n (%)

White 11 (92) 16 (94)

Black 0 (0) 1 (6)

More than 1 race 1 (8) 0 (0)
Ethnicity, n (%)

Hispanic or Latino 1 (8) 0 (0)

Not Hispanic or Latino 11 (92) 16 (94)

Unknown/not reported 0 (0) 1 (6)
Setting, n (%)

Suburban 10 (83) 10 (59)

Urban 2 (17) 4 (23)

Rural 0 (0) 3 (18)
CGMe use, n (%)

Yes 8 (67) 13 (77)

No 4 (33) 4 (23)
Insulin pump use, n (%)

Yes 6 (50) 14 (82)

No 6 (50) 3 (18)
Tubeless pump use among subset of pump users, n (%) 5 (83) 7 (50)
Distance to provider, n (%)

0-10 miles 3 (25) 4 (23)

11-20 miles 2 (17) 3 (18)

21-50 miles 7 (58) 6 (35)

>50 miles 0 (0) 4 (23)
Frequency of provider visits (usual care is every 3 months), n (%)

<3 months 1 (8) 0 (0)

3-6 months 11 (927) 16 (94)

>6 months 0 (0) 1 (6)
ABAS-3f GACg standard score, mean (95% CI) 71.2 (67.9-74.4) N/A

aT1D: type 1 diabetes.

bASD: autism spectrum disorder.

cHbA1c: hemoglobin A1c.

dN/A: not applicable.

eCGM: continuous glucose monitoring.

fABAS-3: adaptive behavior assessment system, third edition.

gGAC: general adaptive composite.